These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 32808557)

  • 1. Real-world observational study of biosimilars in inflammatory arthritis treatment: a systematic literature review.
    Kim JW; Jung JY; Suh CH
    Expert Opin Biol Ther; 2021 Jan; 21(1):57-73. PubMed ID: 32808557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review.
    García-Beloso N; Altabás-González I; Samartín-Ucha M; Gayoso-Rey M; De Castro-Parga ML; Salgado-Barreira Á; Cibeira-Badia A; Piñeiro-Corrales MG; González-Vilas D; Pego-Reigosa JM; Martínez-López de Castro N
    Br J Clin Pharmacol; 2022 Feb; 88(4):1529-1550. PubMed ID: 34622969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioequivalence of Biosimilar Tumor Necrosis Factor-α Inhibitors Compared With Their Reference Biologics: A Systematic Review.
    Chingcuanco F; Segal JB; Kim SC; Alexander GC
    Ann Intern Med; 2016 Oct; 165(8):565-574. PubMed ID: 27479870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory diseases: Integrating biosimilars into clinical practice.
    Feldman SR
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S16-21. PubMed ID: 26058549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
    Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
    Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilars: implications for rheumatoid arthritis therapy.
    Cohen S; Kay J
    Curr Opin Rheumatol; 2017 May; 29(3):260-268. PubMed ID: 28306596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars in Dermatology: Current Situation (Part II).
    Puig L; Carretero G; Daudén E; Ferrándiz C; Marrón SE; Martorell A; Pérez-Suárez B; Rodriguez-Cerdeira C; Ruiz-Villaverde R; Sánchez-Carazo JL; Velasco M;
    Actas Dermosifiliogr; 2015 Sep; 106(7):550-4. PubMed ID: 26049964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of Serious Infections and Design of Utilization and Safety Studies for Biologic and Biosimilar Surveillance.
    Zhang J; Sridhar G; Barr CE; Eichelberger B; Lockhart CM; Marshall J; Clewell J; Accortt NA; Curtis JR; Holmes C; McMahill-Walraven CN; Brown JS; Haynes K
    J Manag Care Spec Pharm; 2020 Apr; 26(4):417-490. PubMed ID: 32223608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients' Understanding and Attitudes Towards Infliximab and Etanercept Biosimilars: Result of a UK Web-Based Survey.
    Aladul MI; Fitzpatrick RW; Chapman SR
    BioDrugs; 2017 Oct; 31(5):439-446. PubMed ID: 28752242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab.
    Feagan BG; Lam G; Ma C; Lichtenstein GR
    Aliment Pharmacol Ther; 2019 Jan; 49(1):31-40. PubMed ID: 30411382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview.
    Song YJ; Nam SW; Suh CH; Choe JY; Yoo DH
    Expert Opin Drug Metab Toxicol; 2023; 19(11):751-768. PubMed ID: 37842948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of biosimilars in the treatment of rheumatoid arthritis : An overview].
    Morf H; Witte T
    Z Rheumatol; 2022 Mar; 81(2):110-117. PubMed ID: 34825948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The global landscape on interchangeability of biosimilars.
    Rathore AS; Stevenson JG; Chhabra H; Maharana C
    Expert Opin Biol Ther; 2022 Feb; 22(2):133-148. PubMed ID: 33567923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world switching and discontinuation outcomes of infliximab biosimilars in patients with rheumatoid arthritis: A scoping review.
    Yin Y; McDermott C; Lockhart C
    J Manag Care Spec Pharm; 2023 Sep; 29(9):985-998. PubMed ID: 37610110
    [No Abstract]   [Full Text] [Related]  

  • 17. Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases.
    Rinaudo-Gaujous M; Paul S; Tedesco ED; Genin C; Roblin X; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2013 Oct; 38(8):914-24. PubMed ID: 24001128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars: a systematic review of published and ongoing clinical trials of antipsoriatics in chronic inflammatory diseases.
    Nast A; Rosumeck S; Seidenschnur K
    J Dtsch Dermatol Ges; 2015 Apr; 13(4):294-300. PubMed ID: 25819235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.
    Braun J; Kay J
    Expert Opin Drug Saf; 2017 Mar; 16(3):289-302. PubMed ID: 28068848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars in ulcerative colitis: When and for who?
    Ilias A; Gonczi L; Kurti Z; Lakatos PL
    Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.